DayOne gains importance
DayOne, a BaselArea.swiss initiative, is creating a world-leading healthcare innovation hub based on the strengths of the Basel region. A further important partner has joined to help achieve this goal.
The Department of Biosystems (D-BSSE) in Basel, which is part of the Federal Institute of Technology in Zurich (ETH), has become the latest partner of DayOne, according to a statement. With the partnership, the department will help promote digital healthcare applications and create a world-leading center for precision medicine.
Its goals are in line with those of BaselArea.swiss, which operates the DayOne initiative. BaselArea.swiss has access to sector and technology experts, doctors and scientists, and is planning to exploit the know-how of around 2,000 healthcare innovators currently based in the Basel region.
The initiative DayOne has six core activities – among them supporting the existing network, launching pioneering projects and providing collaborative workspaces. Another aspect is helping companies from abroad to settle in the Basel region, which BaselArea.swiss specializes in. Furthermore the initiative announced news concerning the other two core activities.
On September 9, the next DayOne Conference will be held at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) in Muttenz in the canton of Basel-Landschaft. Entitled “Shaping the Future of Health”, the conference is expected to attract around 400 innovators, patients and experts. It will look at topics including digitalization and ethics, and will showcase innovations from the DayOne Accelerator and others.
The accelerator is the initiative’s sixth core activity. BaselArea.swiss and the partner organizations received more than 150 applications for the accelerator, twice as many as last year. The 16 companies considered for the first round of the accelerator can present their projects at the DayOne Conference. Four companies will then be selected for funding under the accelerator from January 2020.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More